• Please log in or register to access this feature.

REVIEW

You have free access to this content

Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer

  1. Lowell Ling,
  2. Janet J Maguire,
  3. Anthony P Davenport*

Article first published online: 20 DEC 2012

DOI: 10.1111/j.1476-5381.2011.01786.x

Issue

British Journal of Pharmacology

British Journal of Pharmacology

Volume 168, Issue 2, pages 283–295, January 2013

Additional Information

How to Cite

Ling, L., Maguire, J. J. and Davenport, A. P. (2013), Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. British Journal of Pharmacology, 168: 283–295. doi: 10.1111/j.1476-5381.2011.01786.x

Author Information

  1. Clinical Pharmacology Unit, University of Cambridge, Cambridge, UK

*Dr A. P. Davenport, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. E-mail: apd10@medschl.cam.ac.uk

Publication History

  1. Issue published online: 20 DEC 2012
  2. Article first published online: 20 DEC 2012
  3. Accepted manuscript online: 25 NOV 2011 01:44AM EST
  4. Received; 20 May 2011; Revised; 14 October 2011; Accepted; 31 October 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (745K)

References

  • Al-Alem L, Bridges PJ, Su W, Gong MC, Iglarz M, Ko C (2007). Endothelin-2 induces oviductal contraction via endothelin receptor subtype A in rats. J Endocrinol 193: 383–391.
  • Alexander SPH, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1–S324.
    Direct Link:
  • Arinami T, Ishikawa M, Inoue A, Yanagisawa M, Masaki T, Yoshida MC et al. (1991). Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet 48: 990–996.
  • Arvidsson K, Nemoto T, Mitsui Y, Ohashi S, Nakanishi H (1998). The solution structure of human endothelin-2 a 1H-NMR and CD study. Eur J Biochem 257: 380–388.
    Direct Link:
  • Bacon CR, Davenport AP (1996). Endothelin receptors in human coronary artery and aorta. Br J Pharmacol 117: 986–992.
    Direct Link:
  • Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR et al. (1999). Expression of endothelin 1 and endothelin a receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720–727.
  • Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J (2011). Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163: 220–233.
    Direct Link:
  • Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S et al. (2006). Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 47: 2049–2056.
  • Bayes M, Rabasseda X, Prous JR (2003). Gateways to clinical trials. Methods Find Exp Clin Pharmacol 25: 317–340.
  • Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D (2009). Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 53: 1309–1317.
  • Bertelsen GA, Rebello S, Gulati A (1992). Characteristics of endothelin receptors in the cerebral cortex and spinal cord of aged rats. Neurobiol Aging 13: 513–519.
  • Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M (2009). Endothelin receptor antagonism and cancer. Eur J Clin Invest 39 (Suppl. 2): 74–77.
    Direct Link:
  • Bloch KD, Eddy RL, Shows TB, Quertermous T (1989). cDNA cloning and chromosomal assignment of the gene encoding endothelin 3. J Biol Chem 264: 18156–18161.
  • Bloch KD, Hong CC, Eddy RL, Shows TB, Quertermous T (1991). cDNA cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal contractor peptide is rat endothelin 2. Genomics 10: 236–242.
  • Bohm F, Pernow J, Lindstrom J, Ahlborg G (2003). ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 104: 143–151.
  • Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ et al. (1998). Chronic oral endothelin type a receptor antagonism in experimental heart failure. Hypertension 31: 766–770.
  • Bridges PJ, Jo M, Al-Alem L, Na G, Su W, Gong MC et al. (2010). Production and binding of endothelin-2 (EDN2) in the rat ovary: endothelin receptor subtype A (EDNRA)-mediated contraction. Reprod Fertil Dev 22: 780–787.
  • Brown MJ, Sharma P, Stevens PA (2000). Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes. J Cardiovasc Pharmacol 35: S41–S43.
  • Cameron IT, Plumpton C, Champeney R, Van Papendorp C, Ashby MJ, Davenport AP (1993). Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium. J Reprod Fertil 98: 251–255.
  • Chang I, Bramall A, Baynash AG, Mcinnes RR, Stewart DJ, Yanagisawa M (2009). Genetic study of ET-2 in mice. Eleventh International Conference on Endothelin, 15.
  • Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119–1123.
  • Chao HH, Hong HJ, Liu JC, Lin JW, Chen YL, Chiu WT et al. (2007). Leptin stimulates endothelin-1 expression via extracellular signal-regulated kinase by epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Eur J Pharmacol 573: 49–54.
  • Chappell PE, Lydon JP, Conneely OM, O'Malley BW, Levine JE (1997). Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 138: 4147–4152.
  • Clapéron A, Rose C, Gane P, Collec E, Bertrand O, Ouimet T (2005). The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive. J Biol Chem 280: 21272–21283.
  • Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T et al. (1998). Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125: 813–824.
  • Corder R, Douthwaite JA, Lees DM, Khan NQ, Viseu dos Santos AC, Wood EG et al. (2001). Endothelin-1 synthesis reduced by red wine. Nature 414: 863–864.
  • Cozza EN, Chiou S, Gomez-Sanchez CE (1992). Endothelin-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol 262: R85–R89.
  • D'Orléans-Juste P, Telemaque S, Claing A (1991). Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro. Br J Pharmacol 104: 440–444.
    Direct Link:
  • D'Orléans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E (2008). Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vascul Pharmacol 49: 51–62.
  • Davenport AP (2002). International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219–226.
  • Davenport AP, Maguire JJ (2006). Endothelin. Handb Exp Pharmacol 176: 295–329.
  • Davenport AP, Kuc RE, Maguire JJ, Harland SP (1995). ETA receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol 26 (Suppl. 3): S265–S267.
  • Davenport AP, Kuc RE, Plumpton C, Mockridge JW, Barker PJ, Huskisson NS (1998). Endothelin-converting enzyme in human tissues. J Mol Histol 30: 359–374.
  • Devesly P, Phillips PE, Johns A, Rubanyi G, Parker-Botelho LH (1990). Receptor kinetics differ for endothelin-1 and endothelin-2 binding to Swiss 3T3 fibroblasts. Biochem Biophys Res Commun 172: 126–134.
  • Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R et al. (2004). Effect of single doses of slv306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 94: 237–239.
  • Douglas SA, Hiley CR (1990). Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat. Br J Pharmacol 101: 81–88.
    Direct Link:
  • Eberle JR, Fecker LF, Orfanos CE, Geilen CC (2002). Endothelin-1 decreases basic apoptotic rates in human melanoma cell lines. J Invest Dermatol 119: 549–555.
  • Elferink JG, de Koster BM (1996). The effect of endothelin-2 (ET-2) on migration and changes in cytosolic free calcium of neutrophils. Naunyn Schmiedebergs Arch Pharmacol 353: 130–135.
  • Emoto N, Yanagisawa M (1995). Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270: 15262–15268.
  • Fecteau MH, Honoré JC, Plante M, Labonté J, Rae GA, Pedro DJ (2005). Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 46: 87–92.
  • Flores JA (2000). Gene expression of endothelin-1 in the porcine ovary: follicular development. Biol Reprod 63: 1377–13782.
  • Gardiner SM, Compton AM, Bennett T (1990). Regional hemodynamic effects of endothelin-2 and sarafotoxin-S6b in conscious rats. Am J Physiol 258: R912–R917.
  • Gardiner SM, Kemp PA, Bennett T (1992). Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats. Br J Pharmacol 107: 584–590.
    Direct Link:
  • Giaid A, Gibson SJ, Herrero MT, Gentleman S, Legon S, Yanagisawa M et al. (1991). Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurones of the human brain. Histochemistry 95: 303–314.
  • Grant K, Loizidou M, Taylor I (2003). Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88: 163–166.
  • Gratton JP, Rae GA, Bkaily G, D'Orléans-Juste P (2000). ET(B) receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit. Hypertension 35: 726–731.
  • Grimshaw MJ, Balkwill FR (2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation – a potential mechanism. Eur J Immunol 31: 480–489.
    Direct Link:
  • Grimshaw MJ, Naylo RS, Balkwill FR (2002a). Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 1: 1273–1281.
  • Grimshaw MJ, Wilson JL, Balkwill FR (2002b). Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 32: 2393–2400.
    Direct Link:
  • Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR (2004). A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64: 2461–2468.
  • Guimaraes CL, Calixto JB, Rae GA (1992). Potent constrictor actions of endothelin-1, endothelin-2, and endothelin-3 in rat isolated portal vein. Hypertension 19 (Suppl. 2): S79–S86.
  • Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C (2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25: 1543–1549.
  • Haq A, Kayali M, Hammami MM, Jaroudi K, al-Sedairy ST (1996). Immunoreactive endothelin-1, endothelin-2 and big endothelin-1 in follicular fluids of women undergoing ovulation induction for in-vitro fertilization. Hum Reprod 11: 269–273.
  • Harland SP, Kuc RE, Pickard JD, Davenport AP (1995). Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol 26 (Suppl. 3): S408–S411.
  • Harris AL (2002). Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38–47.
  • Haynes WG, Webb DJ (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852–854.
  • Hickey KA, Rubanyi G, Paul RJ, Highsmith RF (1985). Characterization of a coro- nary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248: C550–C556.
  • Hocher B, Liefeldt L, Thone-Reineke C, Orzechowski HD, Distler A, Bauer C et al. (1996). Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28: 196–201.
  • Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A et al. (1994). Targeted and natural (piebald-lethal) mutations of the endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267–1276.
  • Howard PG, Plumpton C, Davenport AP (1992). Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 10: 1379–1386.
  • Inoue A, Yanagisawa M, Kimura S, Kasuva Y, Miyauchi T, Goto K et al. (1989). The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Nat Acad Sci USA 86: 2863–2867.
  • Ishida N, Tsujioka K, Tomoi M, Saida K, Mitsui Y (1989). Differential activities of two distinct endothelin family peptides on ileum and coronary artery. FEBS Lett 247: 337–340.
  • Iwashima A, Kobayashi M, Saida K, Kagamu H, Ohashi S, Arakawa M et al. (1997). Contraction and intracellular calcium-ion elevation of cultured human aortic smooth muscle cells by endothelin-1, vasoactive intestinal contractor (VIC) and the derivatives. In Vitro Cell Dev Biol Anim 33: 751–756.
  • Jankovic SM, Jankovic SV, Lukic G, Radonjic V, Cupara S, Stefanovic S (2009). Contractile effects of endothelins on isolated ampullar segment of human oviduct in luteal phase of menstrual cycle. Pharmacol Res 59: 69–73.
  • Johnstrom P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC et al. (2005). Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 144: 115–122.
    Direct Link:
  • Kakinuma Y, Miyauchi T, Kobayashi T, Yuki K, Maeda S, Sakai S et al. (1999). Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. Life Sci 65: 1671–1683.
  • Kalra PR, Moon JC, Coats AJ (2002). Do results of the enable (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195–197.
  • Karet FE, Davenport AP (1996). Localization of endothelin peptides in human kidney. Kidney Int 49: 382–387.
  • Kim J, Bagchi IC, Bagchi MK (2009). Signaling by hypoxia-inducible factors is critical for ovulation in mice. Endocrinology 150: 3392–3400.
  • Klipper E, Levit A, Mastich Y, Berisha B, Schams D, Meidan R (2010). Induction of endothelin-2 expression by luteinizing hormone and hypoxia: possible role in bovine corpus luteum formation. Endocrinology 151: 1914–1922.
  • Ko C, Gieske MC, Al-Alem L, Hahn Y, Su W, Gong MC et al. (2006). Endothelin-2 in ovarian follicle rupture. Endocrinology 147: 1770–1779.
  • Kojima K, Nihei Z (1995). Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol 4: 309–315.
  • Kurihara H, Kurihara Y, Yazaki Y (2001). Lessons from gene deletion in the endothelin system. Handb Exp Pharmacol 152: 141–154.
  • Lambert GL, Barker S, Corder R (1998). Comparison of the regulation of endothelin-2 and endothelin-converting enzyme-1 b [correction of beta] by forskolin and TNF-alpha in ACHN cells. J Cardiovasc Pharmacol 31 (Suppl. 1): S49–S51.
  • Lambert GL, Barker S, Lees DM, Corder R (2000). Endothelin-2 synthesis is stimulated by the type-1 tumour necrosis factor receptor and cAMP: comparison with endothelin-converting enzyme-1 expression. J Mol Endocrinol 24: 273–283.
  • Landan G, Bdolah A, Wollberg Z, Kochva E, Graur D (1991). The evolutionary history of the sarafotoxin/endothelin/endothelin-like superfamily. J Cardiovasc Pharmacol 17 (Suppl. 7): S517–S519.
  • Lee ME, Bloch KD, Clifford JA, Quertermous T (1990). Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem 265: 10446–10450.
  • Lee S, Lin M, Mele A, Farmar J, Russo D et al. (1999). Proteolytic processing of big endothelin-3 by the Kell blood group protein. Blood 94: 1440–1450.
  • Liefeldt L, Rylski B, Walcher F, Manhart J, Kron S, Rosenke YW et al. (2010). Effects of transgenic endothelin-2 overexpression on diabetic cardiomyopathy in rats. Eur J Clin Invest 40: 203–210.
    Direct Link:
  • Lin WW, Lee CY (1992). Intestinal relaxation by endothelin isopeptides: involvement of Ca(2+)-activated K+ channels. Eur J Pharmacol 219: 355–360.
  • Lydon JP, Demayo FP, Funk CR, Mani S, Hughes AR, Montgomery CA et al. (1995). Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9: 2266–2278.
  • McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD (2002). Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci 71: 1893–1904.
  • Maguire JJ, Davenport AP (1995). ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 115: 191–197.
    Direct Link:
  • Maguire JJ, Kuc RE, Davenport AP (2001). Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro. Br J Pharmacol 134: 1360–1366.
    Direct Link:
  • Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS, Davenport AP (1992). Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol 5: 175–182.
  • Marone G, DE Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A (1995). Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31: 1–18.
  • Masuo Y, Ishikawa Y, Kozakai T, Uchide T, Komatsu Y, Saida K (2003). Vasoactive intestinal contractor/endothelin-2 gene expression in the murine central nervous system. Biochem Biophys Res Commun 300: 661–668.
  • Matsumoto H, Suzuki N, Onda H, Fujino M (1989). Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 164: 74–80.
  • Matsumoto H, Suzuki N, Kitada C, Fujino M (1994). Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides 15: 505–510.
  • Mattera GG, Eglezos A, Renzetti AR, Mizrahi J (1993). Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan. Br J Pharmacol 110: 331–337.
    Direct Link:
  • Meidan R, Levy N (2007). The ovarian endothelin network: an evolving story. Trends Endocrinol Metab 18: 379–385.
  • de la Monte SM, Quertermous T, Hong CC, Bloch KD (1995). Regional and maturation-associated expression of endothelin 2 in rat gastrointestinal tract. J Histochem Cytochem 43: 203–209.
  • Morton AJ, Davenport AP (1992). Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin s6b. Brain Res 581: 299–306.
  • Na G, Bridges PJ, Koo Y, Ko C (2008). Role of hypoxia in the regulation of periovulatory edn2 expression in the mouse 1. Can J Physiol Pharmacol 2: 310–319.
  • Nagai T, Ogimoto A, Okayama H, Ohtsuka T, Shigematsu Y, Hamada M et al. (2007). A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy. Circ J 71: 1932–1936.
  • Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M et al. (1993). High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am J Gastroenterol 88: 248–252.
  • Negus RP, Turner L, Burke F, Balkwill FR (1998). Hypoxia down-regulates mcp-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63: 758–765.
  • O'Reilly G, Charnock-Jones DS, Davenport AP, Cameron IT, Smith SK (1992). Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle. J Clin Endocrinol Metab 75: 1545–1549.
  • O'Reilly G, Charnock-Jones DS, Cameron IT, Smith SK, Davenport AP (1993a). Endothelin-2 mRNA splice variants detected by RT-PCR in cultured human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 22 (Suppl. 8): S18–S21.
  • O'Reilly G, Charnock-Jones DS, Morrison JJ, Cameron IT, Davenport AP, Smith SK (1993b). Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun 193: 834–840.
  • Ohkubo S, Ogi K, Hosoya M, Matsumoto H, Suzuki N, Kimura C et al. (1990). Specific expression of human endothelin-2 (ET-2) gene in a renal adenocarcinoma cell line. Molecular cloning of cDNA encoding the precursor of ET-2 and its characterization. FEBS Lett 274: 136–140.
  • Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T et al. (1991). Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266: 23251–23256.
  • Packer M, Mcmurray J, Massie B, Caspi A, Charlon V, Cohensolal A et al. (2005). Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11: 12–20.
  • Palanisamy GS, Cheon YP, Kim J, Kannan A, Li Q, Sato M et al. (2006). A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice. Mol Endocrinol 20: 2784–2795.
  • Paulino EC, Steil AA, Jancar S (2006). Effect of endothelins on human neutrophil activation by immune complexes. Int Immunopharmacol 6: 1119–1125.
  • Plumpton C, Champeney R, Ashby MJ, Kuc RE, Davenport AP (1993). Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol 22 (Suppl. 8): S26–S28.
  • Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP (1996). Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 90: 37–46.
  • Poli E, Barboso G, Casoli C, Starcich R, Bertaccini G (1991a). Positive inotropic effect of endothelin-2 on human atrium preparations in vitro. Cardioscience 2: 99–104.
  • Poli E, Casoli C, Spaggiari I, Starcich R, Bertaccini G (1991b). Contractile effect of endothelin-2 on the isolated human saphenous vein. Arch Int Pharmacodyn Ther 313: 108–119.
  • Rodriguez-Pascual F, Redondo-Horcajo M, Magan-Marchal N, Lagares D, Martinez-Ruiz A, Kleinert H et al. (2008). Glyceraldehyde-3-phosphate dehydrogenase regulates endothelin-1 expression by a novel, redox-sensitive mechanism involving mRNA stability. Mol Cell Biol 28: 7139–7155.
  • Roubert P, Gillard V, Plas P, Chabrier PE, Braquet P (1991). Binding characteristics of endothelin isoforms (et-1, ET-2, and et-3) in vascular smooth muscle cells. J Cardiovasc Pharmacol 17 (Suppl. 7): S104–S108.
  • Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903.
  • Saida K, Mitsui Y, Ishida N (1989). A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem 264: 14613–14616.
  • Saida K, Hashimoto M, Mitsui Y, Ishida N, Uchide T (2000). The prepro vasoactive intestinal contractor (VIC)/endothelin-2 gene (EDN2): structure, evolution, production, and embryonic expression. Genomics 64: 51–61.
  • Saida K, Kometani N, Uchide T, Mitsui Y (2002). Sequence analysis and expression of the mouse full-length vasoactive intestinal contractor/endothelin-2 gene (EDN2): comparison with the endothelin-1 gene (EDN1). Clin Sci (Lond) 103 (Suppl. 48): S84–S89.
  • Sakai S, Miyauchi T, Kobayashi M, Yamagushi I, Goto K, Sugishita Y (1996). Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353–355.
  • Schoeffter P, Randriantsoa A (1993). Differences between endothelin receptors mediating contraction of guinea-pig aorta and pig coronary artery. Eur J Pharmacol 249: 199–206.
  • Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, et al. (2012). The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci, doi: 10.1016/j.lfs.2012.03.022.
  • Sharma P, Hingorani A, Jia H, Hopper R, Brown MJ (1999). Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. J Hypertens 17: 1281–1287.
  • Shimada K, Takahashi M, Tanzawa K (1994). Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 269: 18275–18278.
  • Shirasuna K, Watanabe S, Oki N, Wijayagunawardane MP, Matsui M, Ohtani M et al. (2006). A cooperative action of endothelin-1 with prostaglandin f(2alpha) on luteal function in the cow. Domest Anim Endocrinol 31: 186–196.
  • Stow LR, Jacobs ME, Wingo CS, Cain BD (2011). Endothelin-1 gene regulation. FASEB J 25: 16–28.
  • Tabrizchi R (2003). Slv-306. Solvay. Curr Opin Investig Drugs 4: 329–332.
  • Takai S, Shiota N, Jin D, Miyazaki M (1998). Chymase processes big-endothelin-2 to endothelin-2-(1-31) that induces contractile responses in the isolated monkey trachea. Eur J Pharmacol 358: 229–233.
  • Takizawa S, Uchide T, Adur J, Kozakai T, Kotake-Nara E, Quan J et al. (2005). Differential expression of endothelin-2 along the mouse intestinal tract. J Mol Endocrinol 35: 201–209.
  • Tanese K, Fukuma M, Ishiko A, Sakamoto M (2010). Endothelin-2 is upregulated in basal cell carcinoma under control of hedgehog signaling pathway. Biochem Biophys Res Commun 391: 486–491.
  • Telemaque S, D'Orléans-Juste P (1991). Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 344: 505–507.
  • Tokito F, Suzuki N, Hosoya M, Matsumoto H, Ohkubo S, Fujino M (1991). Epidermal growth factor (EGF) decreased endothelin-2 (ET-2) production in human renal adenocarcinoma cells. FEBS Lett 295: 17–21.
  • Turner AJ, Murphy LJ (1996). Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 51: 91–102.
  • Turner L, Scotton C, Negus R, Balkwill F (1999). Hypoxia inhibits macrophage migration. Eur J Immunol 29: 2280–2287.
    Direct Link:
  • Uchide T, Masuda H, Mitsui Y, Saida K (1999). Gene expression of vasoactive intestinal contractor/endothelin-2 in ovary, uterus and embryo: comprehensive gene expression profiles of the endothelin ligand-receptor system revealed by semi-quantitative reverse transcription-polymerase chain reaction analysis in adult mouse tissues and during late embryonic development. J Mol Endocrinol 22: 161–171.
  • Uchide T, Adur J, Fukamachi T, Saida K (2000). Quantitative analysis of endothelin-1 and vasoactive intestinal contractor/endothelin-2 gene expression in rats by real-time reverse transcriptase polymerase chain reaction. J Cardiovasc Pharmacol 36: S5–S8.
  • Vallender TW, Lahn BT (2006). Localized methylation in the key regulator gene endothelin-1 is associated with cell type-specific transcriptional silencing. FEBS Lett 580: 4560–4566.
  • Walles B, Gröschel-Stewart U, Kannisto P, Owman C, Sjöberg NO, Unsicker K (1990). Immunocytochemical demonstration of contractile cells in the human ovarian follicle. Experientia 46: 682–683.
  • Watanabe T (1975). Proteolytic activity of mycoplasma salivarium and mycoplasma orale 1. Med Microbiol Immunol 161: 127–132.
  • Wright C, Cody W, Dunbar JJ, Doherty A, Hingorani G, Rapundalo S (1994). Characterization of endothelins as chemoattractants for human neutrophils. Life Sci 55: 1633–1641.
  • Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE et al. (1998). Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125: 825–836.
  • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415.
  • Yap EY, Battistini B, McKay KO (2000). Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi. Br J Pharmacol 129: 170–176.
    Direct Link:
  • Yeligar S, Tsukamoto H, Kalra VK (2009). Ethanol induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxiainducible factor-1alpha and microrNA-199. J Immunol 183: 5232–5243.
  • Yen H, Zhang Y, Penfold S, Rollins BJ (1997). Mcp-1-mediated chemotaxis requires activation of signal transduction pathways. J Leukoc Biol 61: 529–532.
  • Yorimitsu K, Shinmi O, Nishiyama M, Moroi K, Sugita Y, Saito T et al. (1992). Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells. Analysis of endothelin-2 biosynthetic pathway. FEBS Lett 314: 395–398.
  • Yorimitsu K, Moroi K, Inagaki N, Saito T, Masuda Y, Masaki T et al. (1995). Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophys Res Commun 208: 721–727.
  • Yoshinaga M, Chijiiwa Y, Misawa T, Harada N, Nawata H (1992). EndothelinB receptor on guinea pig small intestinal smooth muscle cells. Am J Physiol 262: G308–G311.
View Full Article (HTML) Get PDF (745K)